NASDAQ:RAREUltragenyx Pharmaceutical Competitors & Alternatives

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and Alnylam Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Ultragenyx Pharmaceutical has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Ultragenyx Pharmaceutical and Alnylam Pharmaceuticals, as reported by MarketBeat.com.

Ultragenyx Pharmaceutical currently has a consensus price target of $81.3571, indicating a potential downside of 9.60%. Alnylam Pharmaceuticals has a consensus price target of $151.2778, indicating a potential downside of 5.70%. Given Alnylam Pharmaceuticals' higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares Ultragenyx Pharmaceutical and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.

Institutional & Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 93.4% of Alnylam Pharmaceuticals shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Beigene (NASDAQ:BGNE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and Beigene's top-line revenue, earnings per share (EPS) and valuation.

Ultragenyx Pharmaceutical has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Ultragenyx Pharmaceutical and Beigene, as reported by MarketBeat.com.

Ultragenyx Pharmaceutical currently has a consensus price target of $81.3571, indicating a potential downside of 9.60%. Beigene has a consensus price target of $202.8111, indicating a potential downside of 0.63%. Given Beigene's higher probable upside, analysts clearly believe Beigene is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares Ultragenyx Pharmaceutical and Beigene's net margins, return on equity and return on assets.

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, Beigene has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.

Institutional & Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 63.8% of Beigene shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 11.0% of Beigene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Ultragenyx Pharmaceutical beats Beigene on 9 of the 14 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and GALAPAGOS NV/S (NASDAQ:GLPG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and GALAPAGOS NV/S's top-line revenue, earnings per share (EPS) and valuation.

GALAPAGOS NV/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than GALAPAGOS NV/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, GALAPAGOS NV/S has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and GALAPAGOS NV/S's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Ultragenyx Pharmaceutical and GALAPAGOS NV/S, as reported by MarketBeat.

Ultragenyx Pharmaceutical currently has a consensus price target of $81.3571, suggesting a potential downside of 9.60%. GALAPAGOS NV/S has a consensus price target of $229.00, suggesting a potential upside of 13.38%. Given GALAPAGOS NV/S's higher probable upside, analysts plainly believe GALAPAGOS NV/S is more favorable than Ultragenyx Pharmaceutical.

Institutional and Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 11.7% of GALAPAGOS NV/S shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 2.9% of GALAPAGOS NV/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

GALAPAGOS NV/S beats Ultragenyx Pharmaceutical on 8 of the 14 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and GRIFOLS S A/S (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and GRIFOLS S A/S's top-line revenue, earnings per share (EPS) and valuation.

GRIFOLS S A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than GRIFOLS S A/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, GRIFOLS S A/S has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and GRIFOLS S A/S's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Ultragenyx Pharmaceutical and GRIFOLS S A/S, as reported by MarketBeat.

Ultragenyx Pharmaceutical currently has a consensus price target of $81.3571, suggesting a potential downside of 9.60%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than GRIFOLS S A/S.

Institutional and Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 17.9% of GRIFOLS S A/S shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Ultragenyx Pharmaceutical and Sarepta Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Ultragenyx Pharmaceutical has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ultragenyx Pharmaceutical has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and Sarepta Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Ultragenyx Pharmaceutical and Sarepta Therapeutics, as reported by MarketBeat.

Ultragenyx Pharmaceutical currently has a consensus price target of $81.3571, suggesting a potential downside of 9.60%. Sarepta Therapeutics has a consensus price target of $198.9091, suggesting a potential upside of 16.90%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Institutional and Insider Ownership

99.9% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 93.1% of Sarepta Therapeutics shares are owned by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ultragenyx Pharmaceutical beats Sarepta Therapeutics on 8 of the 14 factors compared between the two stocks.

Teva Pharmaceutical Industries (NYSE:TEVA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Institutional and Insider Ownership

48.8% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 99.9% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Teva Pharmaceutical Industries and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and target prices for Teva Pharmaceutical Industries and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

Teva Pharmaceutical Industries currently has a consensus target price of $11.50, suggesting a potential upside of 0.88%. Ultragenyx Pharmaceutical has a consensus target price of $81.3571, suggesting a potential downside of 9.60%. Given Teva Pharmaceutical Industries' higher possible upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Ultragenyx Pharmaceutical.

Risk & Volatility

Teva Pharmaceutical Industries has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500.

Valuation & Earnings

This table compares Teva Pharmaceutical Industries and Ultragenyx Pharmaceutical's gross revenue, earnings per share and valuation.

Ultragenyx Pharmaceutical has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Summary

Ultragenyx Pharmaceutical beats Teva Pharmaceutical Industries on 8 of the 14 factors compared between the two stocks.